Abstract
Ovarian cancer is the most lethal of gynecologic malignancies. Currently, standard treatment for epithelial ovarian cancer consists of surgical debulking followed by adjuvant chemotherapy with a platinum-based drug coupled with paclitaxel. While initial response to chemotherapy is high, the majority of patients develop recurrent disease which is characterized by chemoresistance. The primary cytotoxic effect of many chemotherapy drugs is mediated by apoptotic response in tumor cells. Recent data indicate that cross talk between the tumor microenvironment and malignant epithelial cells can influence apoptotic response as well. The identification of molecules involved in the regulation and execution of apoptosis, and their alterations in ovarian carcinoma have provided new insights into the mechanism behind the development of chemoresistance in this disease. Our challenge now is to devise strategies to circumvent cell death defects and ultimately improve response to treatment in ovarian carcinoma patients.
Keywords: Apoptosis, chemoresistance, ovarian carcinoma, tumor microenvironment
Current Cancer Drug Targets
Title: Too Much of a Good Thing: Suicide Prevention Promotes Chemoresistance in Ovarian Carcinoma
Volume: 10 Issue: 6
Author(s): K. Pennington, H. Pulaski, M. Pennington and J.R. Liu
Affiliation:
Keywords: Apoptosis, chemoresistance, ovarian carcinoma, tumor microenvironment
Abstract: Ovarian cancer is the most lethal of gynecologic malignancies. Currently, standard treatment for epithelial ovarian cancer consists of surgical debulking followed by adjuvant chemotherapy with a platinum-based drug coupled with paclitaxel. While initial response to chemotherapy is high, the majority of patients develop recurrent disease which is characterized by chemoresistance. The primary cytotoxic effect of many chemotherapy drugs is mediated by apoptotic response in tumor cells. Recent data indicate that cross talk between the tumor microenvironment and malignant epithelial cells can influence apoptotic response as well. The identification of molecules involved in the regulation and execution of apoptosis, and their alterations in ovarian carcinoma have provided new insights into the mechanism behind the development of chemoresistance in this disease. Our challenge now is to devise strategies to circumvent cell death defects and ultimately improve response to treatment in ovarian carcinoma patients.
Export Options
About this article
Cite this article as:
Pennington K., Pulaski H., Pennington M. and Liu J.R., Too Much of a Good Thing: Suicide Prevention Promotes Chemoresistance in Ovarian Carcinoma, Current Cancer Drug Targets 2010; 10 (6) . https://dx.doi.org/10.2174/156800910791859498
DOI https://dx.doi.org/10.2174/156800910791859498 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Structural Characterization of Carbohydrates by Fourier Transform Tandem Mass Spectrometry
Current Proteomics Meta-heuristic Techniques to Train Artificial Neural Networks for Medical Image Classification: A Review
Recent Advances in Computer Science and Communications Poly(ADP-ribosylation) and Neoplastic Transformation: Effect of PARP Inhibitors
Current Pharmaceutical Biotechnology Orai1 and Transient Receptor Potential Channels as Novel Molecular Targets to Impair Tumor Neovascularization in Renal Cell Carcinoma and other Malignancies
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Biological Evaluation of Some New Indolizine Derivatives as Antitumoral Agents
Letters in Drug Design & Discovery CYP24A1 as a Potential Target for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Molecular Docking and 3D-QSAR Studies on Quinolone-based HDAC Inhibitors
Letters in Drug Design & Discovery Cells Under Pressure – Treatment of Eukaryotic Cells with High Hydrostatic Pressure, from Physiologic Aspects to Pressure Induced Cell Death
Current Medicinal Chemistry Cytotoxic Nucleoside Analogues: Different Strategies to Improve their Clinical Efficacy
Current Medicinal Chemistry Regulation of Angiogenesis by the Small Heat Shock Protein αB-Crystallin
Current Angiogenesis (Discontinued) Recent Progress of Src SH2 and SH3 Inhibitors as Anticancer Agents
Current Medicinal Chemistry Influence of Genetic Factors on the Development of Breast Cancer in the Older Woman
Current Aging Science Genetic and Epigenetic Studies for Determining Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets Structure-based Virtual Screening for the Identification of High-affinity Small Molecule Towards STAT3 for the Clinical Treatment of Osteosarcoma
Current Topics in Medicinal Chemistry Abrogation of the G2 Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53-Deficient Tumor Cells to DNA-Damaging Agents
Current Clinical Pharmacology In Silico Prediction and Validation of Oxygen-Regulated Protein N-myc Downstream Regulated Gene 3 and Virtual Screening of Competitive Inhibitors of L-Lactate as Therapeutics
Letters in Drug Design & Discovery Role of Angiopoietin-like 4 (ANGPTL4), a Member of Matricellular Proteins: from Homeostasis to Inflammation and Cancer Metastasis
Current Angiogenesis (Discontinued) Bioluminescence Imaging in Rodents: When Light Illuminates Cancer Research
Current Molecular Imaging (Discontinued) LncRNAs as Architects in Cancer Biomarkers with Interface of Epitranscriptomics- Incipient Targets in Cancer Therapy
Current Cancer Drug Targets Attacking c-Myc: Targeted and Combined Therapies for Cancer
Current Pharmaceutical Design